South African mutations of the CCR5 coreceptor for HIV modify interaction with chemokines and HIV envelope protein

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 4, 2010, Pages 352-359

  Folefoc, Asongna T ^a   Fromme, Bernhard J ^a,b   Katz, Arieh A ^a   Flanagan, Colleen A ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Bioscience Division Elsies River   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

CCR5 coreceptor mutants; CCR5 expression; Envdirected fusion

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ENVELOPE PROTEIN; MUTANT PROTEIN; CHEMOKINE; COMPLEMENTARY DNA; DNA; GAG PROTEIN; PRIMER DNA; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SOUTH AFRICA; CD4+ T LYMPHOCYTE; CELL FUSION; CELL LINE; CYTOLOGY; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY; METABOLISM; MUTATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

CD4-POSITIVE T-LYMPHOCYTES; CELL FUSION; CELL LINE; CHEMOKINES; DNA; DNA PRIMERS; DNA, ANTISENSE; FLOW CYTOMETRY; GENE PRODUCTS, GAG; HIV; HIV INFECTIONS; HUMANS; KIDNEY; MUTATION; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; SOUTH AFRICA; TRANSFECTION; VIRAL ENVELOPE PROTEINS;

EID: 77955491861     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e0c7b2     Document Type: Article

References (66)

1. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955-1958.
2. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661-666.
3. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996;85:1149-1158.
4. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381: 667-673.
5. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
6. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
7. Broder CC, Collman RG. Chemokine receptors and HIV. J Leukoc Biol. 1997;62:20-29.
8. Weiss RA. Gulliver's travels in HIVland. Nature. 2001;410:963-967.
9. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-877.
10. Raport CJ, Gosling J, Schweickart VL, et al. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem. 1996; 271:17161-17166.
11. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci\USA. 2008;105: 7552-7557.
12. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
13. Petersen DC, Kotze MJ, Zeier MD, et al. Novel mutations identified using a comprehensive CCR5-denaturing gradient gel electrophoresis assay. AIDS. 2001;15:171-177.
14. Jlizi A, Edouard J, Fadhlaoui-Zid K, et al. Identification of the CCR5-Delta32 HIV resistance allele and new mutations of the CCR5 gene in different Tunisian populations. Hum Immunol. 2007;68:993-1000.
15. Carrington M, Kissner T, Gerrard B, et al. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet. 1997;61:1261-1267.
16. Shieh B, Liau YE, Yan YP, et al. Alleles that may influence HIV-1 pathogenesis in Chinese subjects. AIDS. 1999;13:421-424.
17. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet. 1998;62:1507-1515.
18. Martinson JJ, Chapman NH, Rees DC, et al. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997;16:100-103.
19. Ma L, Dudoit Y, Tran T, et al. Biochemical and HIV-1 coreceptor properties of K26R, a new CCR5 Variant in China's Sichuan population. J Acquir Immune Defic Syndr. 2005;39:38-43.
20. Hayes VM, Petersen DC, Scriba TJ, et al. African-based CCR5 single-nucleotide polymorphism associated with HIV-1 disease progression. AIDS. 2002;16:2229-2231.
21. Samson M, Labbe O, Mollereau C, et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35:3362-3367.
22. Combadiere C, Ahuja SK, Tiffany HL, et al. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol. 1996;60:147-152.
23. Blanpain C, Migeotte I, Lee B, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood. 1999;94: 1899-1905.
24. Nibbs RJ, Yang J, Landau NR, et al. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem. 1999;274:17478-17483.
25. Menten P, Struyf S, Schutyser E, et al. The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest. 1999;104:R1-R5.
26. Ward SG, Westwick J. Chemokines: understanding their role in T-lymphocyte biology. Biochem J. 1998;333:457-470.
27. Doranz BJ, Lu ZH, Rucker J, et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol. 1997;71:6305-6314.
28. Dragic T, Trkola A, Lin SW, et al. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol. 1998;72:279-285.
29. Farzan M, Choe H, Vaca L, et al. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol. 1998;72: 1160-1164.
30. Rabut GE, Konner JA, Kajumo F, et al. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage-and dualtropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:3464-3468.
31. Ross TM, Bieniasz PD, Cullen BR. Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. J Virol. 1998;72: 1918-1924.
32. Blanpain C, Doranz BJ, Vakili J, et al. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem. 1999; 274:34719-34727.
33. Howard OM, Shirakawa AK, Turpin JA, et al. Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function. J Biol Chem. 1999;274: 16228-16234.
34. Kazmierski W, Bifulco N, Yang H, et al. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem. 2003;11:2663-2676.
35. Zaitseva M, Peden K, Golding H. HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim Biophys Acta. 2003;1614:51-61.
36. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16:1201-1210.
37. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr Pharm Des. 2004;10: 2041-2062.
38. Dragic T, Trkola A, Thompson DA, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci\USA. 2000;97:5639-5644.
39. Tsamis F, Gavrilov S, Kajumo F, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol. 2003; 77:5201-5208.
40. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol. 2008;73:789-800.
41. Maeda K, Das D, Ogata-Aoki H, et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem. 2006;281: 12688-12698.
42. Seibert C, Ying W, Gavrilov S, et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology. 2006;349:41-54.
43. Kostenis E. Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci. 2001;22:560-564.
44. van Harmelen J, Williamson C, Kim B, et al. Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses. 2001;17:1527-1531.
45. Williamson C, Morris L, Maughan MF, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Human Retroviruses. 2003;19:133-144.
46. Jenkinson S, McCoy D, Kerner S, et al. Development of a high-throughput viral-free assay for the measurement of CCR5-mediated HIV/cell fusion. Receptors Channels. 2003;9:117-123.
47. Lee B, Sharron M, Blanpain C, et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem. 1999;274: 9617-9626.
48. Millar RP, Davidson J, Flanagan C, et al. Ligand binding and second-messenger assays for cloned Gq/G11-coupled neuropeptide receptors: The GnRH receptor. Methods Neurosci. 1995;25:145-162.
49. Flanagan CA, Fromme BJ, Davidson JS, et al. A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. Endocrinology. 1998;139:4115-4119.
50. Ansari-Lari MA, Liu XM, Metzker ML, et al. The extent of genetic variation in the CCR5 gene. Nat Genet. 1997;16:221-222.
51. Baldwin JM. The probable arrangement of the helices in G protein-coupled receptors. Embo J. 1993;12:1693-1703.
52. Mirzadegan T, Benko G, Filipek S, et al. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry. 2003;42:2759-2767.
53. Ballesteros JA, Jensen AD, Liapakis G, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem. 2001; 276:29171-29177.
54. Springael JY, de Poorter C, Deupi X, et al. The activation mechanism of chemokine receptor CCR5 involves common structural changes but a different network of interhelical interactions relative to rhodopsin. Cell Signal. 2007;19:1446-1456.
55. Gosling J, Monteclaro FS, Atchison RE, et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci\USA. 1997;94:5061-5066.
56. Farzan M, Choe H, Martin KA, et al. HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem. 1997;272:6854-6857.
57. Aramori I, Ferguson SS, Bieniasz PD, et al. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. Embo J. 1997;16:4606-4616.
58. Amara A, Vidy A, Boulla G, et al. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J Virol. 2003;77:2550-2558.
59. Olson WC, Rabut GE, Nagashima KA, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol. 1999;73: 4145-4155.
60. Wu L, LaRosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med. 1997;186:1373-1381.
61. Doms RW, Peiper SC. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology. 1997;235:179-190.
62. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9:551-562.
63. Farzan M, Mirzabekov T, Kolchinsky P, et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999;96:667-676.
64. Monigatti F, Hekking B, Steen H. Protein sulfation analysis\a primer. Biochim Biophys Acta. 2006;1764:1904-1913.
65. Lim JK, Glass WG, McDermott DH, et al. CCR5: no longer a "good for nothing" gene\chemokine control of West Nile virus infection. Trends Immunol. 2006;27:308-312.
66. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis. 2008;197:262-265.